PDCD1 and melanoma: The result suggests that the synergistic anti-PD-1/G007-LK treatment effect seen in wild-type B16-F10 tumors (Fig. 3a) is, to a considerable part, attributed to G007-LK-induced reduction of β-catenin levels in the melanoma cells of the tumors.